Clinical trial
Campath-1H + FK506 and Methylprednisolone for GVHD
NCT00109993 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00109993 |
|---|---|
| Title | Campath-1H + FK506 and Methylprednisolone for GVHD |
| Official title | Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma and 2 more |
| Intervention type | Biological, Drug |
| Interventions | alemtuzumab, methylprednisolone, tacrolimus |
| Enrollment | 34 |
| Start date | Jan 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | May 1, 2007 |
| First posted | May 4, 2005 |
| Last update posted | Jun 11, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: